Good
Mostly Aligned
Patient Risk:
Low
Summary
Most statements are consistent with the provided label excerpts regarding route-specific administration and renal-dose adjustment concepts. One statement is unsupported/incorrect: the excerpt does not state that methylnaltrexone clearance is partly renal.
Category Scores
Accurate Statements
Relistor dosing depends on the condition being treated and the route used (oral vs. injection).
Supported by Dose/Administration section showing different regimens by indication and by formulation/route (e.g., 2.2 tablets vs injection; 2.4 renal impairment dosing by indication and formulation/route).
Dosing of methylnaltrexone typically needs adjustment in renal impairment.
Supported by 2.4 Dosage in Patients with Renal Impairment and 8.6 Renal Impairment (dose reduction recommended in moderate/severe renal impairment).
Relistor can be administered subcutaneously (injection) in many opioid-induced constipation (OIC) settings.
Supported by 2.2 (injection given subcutaneously once daily for chronic non-cancer pain OIC) and 2.3 (subcutaneous injection for advanced illness OIC).
Relistor can be administered orally when the oral formulation is appropriate.
Supported by 2.2 (tablets taken orally once daily in chronic non-cancer pain OIC).
Exact Relistor dosing depends on the formulation and route.
Supported by 2.2 showing tablets (oral) vs injection (subcutaneous) have different recommended doses, and 2.4 showing renal impairment doses differ by tablets vs injection.
Relistor dosing differs by route and product strength.
Supported by 2.2 (different dosing by route/formulation) and 2.3 (different injection doses 8 mg or 12 mg referenced by pre-filled syringe).
Unsupported Statements
Methylnaltrexone (Relistor) is cleared partly through the kidneys.
Not supported by the provided label excerpts. The excerpts discuss increased exposure and recommended dose reduction in renal impairment (2.4, 8.6) but do not explicitly state the clearance route (e.g., 'cleared partly through the kidneys').
Contradictions
Important Omissions
Renal impairment dosing is specifically provided as tablets 150 mg once daily in the morning and injection 6 mg subcutaneously once daily for moderate/severe renal impairment in chronic non-cancer pain OIC (2.4), rather than a general statement that dosing 'needs adjustment.'
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only unsupported claim is about renal clearance mechanism, which is not directly a dosing instruction. Other statements align with label-supported dose adjustments in renal impairment and route/formulation differences.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Unsupported claim that methylnaltrexone is cleared partly through the kidneys; the excerpts instead support increased exposure and dose reduction without specifying clearance pathway.
Suggested Improvement
Replace the clearance-mechanism statement with label-supported wording (e.g., renal impairment increases exposure and requires dose reduction) and, if discussing renal impairment, include the specific recommended tablet and injection doses from 2.4.